Clinical Trials Logo

Clinical Trial Summary

Primary hyperoxaluria is an inborn error of metabolism that results in marked overproduction of oxalate by the liver. The excess oxalate causes kidney failure and can cause severe systemic disease due to oxalate deposition in multiple body tissues.

Metabolic pathways that lead to oxalate are poorly understood, but recent evidence suggests that hydroxyproline may play a role. Sources of hydroxyproline include the diet and bone turnover. If hydroxyproline can be confirmed as a significant factor in primary hyperoxaluria, diet modification might be of value in reducing the severity of disease.

This protocol, in which hydroxyproline labelled with a cold isotope is infused intravenously in patients with primary hyperoxaluria, will allow the researchers to measure the amount of oxalate produced from hydroxyproline. The contribution of hydroxyproline metabolism to the amount of oxalate excreted in urine in will be able to be determined for patients with each of the known types of primary hyperoxaluria.


Clinical Trial Description

The purpose of this study is to determine the contribution of hydroxyproline metabolism to urinary oxalate and glycolate excretion in patients with primary hyperoxaluria.

Oxalic acid (COOH)2 is an end product of metabolism that is synthesized mainly in the liver. The researchers have estimated that 10 - 20 mg is synthesized in the body of healthy adults each day. The main precursor of oxalate is glyoxylate (CHO•COOH). The bulk of the glyoxylate formed is normally transaminated to glycine (NH2•CH2•COOH) by alanine: glyoxylate aminotransferase (AGT) or reduced to glycolate (CHOH•COOH) by glyoxylate reductase (GR). Less than 10% of the glyoxylate is oxidized to oxalate by lactate dehydrogenase (LDH). In individuals with the disease, primary hyperoxaluria, AGT, GR, or hydroxy-oxoglutarate aldolase (HOGA) enzyme is deficient and the amount of oxalate synthesized by the liver increases to 80 - 300 mg per day. The increased oxalate excreted in urine can cause damage to kidney tissue. Calcium oxalate stones may form in the kidney or calcium oxalate crystals may deposit in renal tubules and the renal parenchyma (nephrocalcinosis). An increased rate of oxalate synthesis could also contribute to idiopathic calcium oxalate stone disease. Understanding the pathways of endogenous oxalate synthesis and identifying strategies that decrease oxalate production could be beneficial for individuals with these diseases.

Hydroxyproline is the primary source of glyoxylate identified in the body. Daily collagen turnover of bone results in the formation of 300 - 450 mg of hydroxyproline, which cannot be re-utilized by the body and is broken down. This metabolism yields 180 - 250 mg of glyoxylate. Further hydroxyproline is obtained from the diet, primarily from meat and gelatin-containing products. The bulk of the glyoxylate formed is converted to glycine by the liver enzyme AGT, some to glycolate and a small amount to oxalate. The proportion of these metabolites is not known with any certainty. In this study, a quantitative estimate of the metabolites formed will provide estimates of the contribution of hydroxyproline turnover to daily oxalate production. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02038543
Study type Interventional
Source Mayo Clinic
Contact
Status Completed
Phase Phase 1/Phase 2
Start date September 2013
Completion date January 2017

See also
  Status Clinical Trial Phase
Withdrawn NCT06138327 - A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria Phase 1
Completed NCT02547805 - Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days Phase 2
Completed NCT02289755 - Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria Phase 2
Completed NCT03095885 - A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria N/A
Recruiting NCT02780297 - Prospective Research Rare Kidney Stones (ProRKS)
Completed NCT01127087 - Oxazyme in Patients With Hyperoxaluria Phase 1/Phase 2
Not yet recruiting NCT05443932 - Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients Phase 4
Completed NCT04756024 - Reference Interval of Spot Urinary Oxalate to Creatinine Ratio in Children
Completed NCT02503345 - Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones Phase 2
Completed NCT00199459 - Proteomic Study of Urinary Stone Disease N/A
Completed NCT04119765 - Plasma Oxalate in Patient With Short Bowel
Completed NCT02404701 - Effect of Over-the-counter Dietary Supplements on Kidney Stone Risk N/A
Completed NCT00283387 - Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria Phase 2
Completed NCT00587041 - Use of Oral Probiotics to Reduce Urinary Oxalate Excretion Phase 1/Phase 2
Completed NCT04571359 - Spot Urine Oxalate to Creatinine Ratio and 24 Hours Urinary Oxalate
Withdrawn NCT00280215 - Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria Phase 3
Completed NCT00588120 - Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria Phase 1